Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography
Children · 27.08.2025 · 12 (9) · 1131
DOI: 10.3390/children12091131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 27.08.2025. Verfasst von Fusako Yamazaki und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KAKENHI, Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development, Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Background/Objectives: This study aimed to investigate the prevalence of liver damage and its associated non-invasive markers and echocardiographic risk factors in patients who underwent surgery for congenital heart disease.
Methods
This retrospective observational study was conducted at a single tertiary-care university hospital in Niigata, Japan. Of 142 patients (ventricular septal defect [VSD] n = 47, tetralogy of Fallot [TOF] n = 67, Fontan n = 28), 52.8% were male [median age: 22.7 years; VSD (24.3 years), TOF (24.0 years), and Fontan (12.5 years)]. Pediatric patients with liver diseases unrelated to congestive liver disease, such as viral hepatitis and alcoholic liver disease, were excluded. We compared non-invasive liver fibrosis age-invariant biomarkers, such as the aspartate aminotransferase-to-platelet ratio index (APRI), and various serum markers and echocardiographic parameters to assess the prevalence and predictors of hepatic fibrosis.
Results
The Fontan circulation group had the highest APRI, followed by the TOF group, while the VSD group had a low risk of APRI elevation. Postoperative TOF patients required monitoring for cirrhosis progression. Inferior vena cava mobility was associated with echocardiographic parameters and fibrosis severity, along with a loss of respiratory variability. The limitations of other cardiac assessments were highlighted by poor anatomical measurements. Gamma-glutamyl transpeptidase (γ-GTP) demonstrated strong discriminatory ability. The optimal cutoff value was 53.0 U/L, suggesting its use as a clinical marker.
Conclusions
Assessing fibrosis is crucial in CHD patients, especially those with late post-TOF repair findings. Non-invasive markers (APRI, γ-GTP, and B-type natriuretic peptide), along with echocardiographic findings, may help detect fibrosis early, enabling timely intervention and improving long-term outcomes. Clinical trial registration: 2020-0199.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.
- Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 950-3198, Japan.
- Division of Thoracic and Cardiovascular Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 950-3198, Japan.
- Department of Cardiovascular Medicine, Niigata University Medical and Dental Hospital, Niigata 950-3198, Japan.
- Department of Business Administration, Aichi Institute of Technology, Toyota 470-0356, Japan.
- Department of General Medicine, School of Medicine, Niigata University, Niigata 950-3198, Japan.
ORCID-Profile: Hiroteru Kamimura, Suguru Miida, Hiroyuki Abe, Takeshi Yokoo, Akihiko Saitoh, Takeshi Kashimura, Takayuki Inomata, Hirofumi Nonaka, Kenya Kamimura, Shuji Terai
Förderung
- KAKENHI
- Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development
- Grant-in-Aid for Scientific Research
- Japan Agency for Medical Research and Development
Zitieren
APA
Yamazaki, F., Kamimura, H., Endo, S., Miida, S., Maruyama, H., Yoshida, T., Kumagai, M., Kimura, N., Abe, H., Sakamaki, A., Yokoo, T., Tsukada, M., Numano, F., Saitoh, A., Watanabe, M., Shiraishi, S., Tsuchida, M., Fujiki, S., Kashimura, T., …, & Terai, S. (2025). Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography. Children, 12(9), 1131. https://doi.org/10.3390/children12091131
Vancouver
Yamazaki F, Kamimura H, Endo S, Miida S, Maruyama H, Yoshida T, et al. Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography. Children. 2025;12(9):1131. doi:10.3390/children12091131
BibTeX
@article{Yamazaki2025,
author = {Yamazaki, Fusako and Kamimura, Hiroteru and Endo, Saori and Miida, Suguru and Maruyama, Hiroki and Yoshida, Tomoaki and Kumagai, Masaru and Kimura, Naruhiro and Abe, Hiroyuki and Sakamaki, Akira and Yokoo, Takeshi and Tsukada, Masanori and Numano, Fujito and Saitoh, Akihiko and Watanabe, Maya and Shiraishi, Shuichi and Tsuchida, Masanori and Fujiki, Shinya and Kashimura, Takeshi and Inomata, Takayuki and Nonaka, Hirofumi and Kamimura, Kenya and Tsuchiya, Atsunori and Terai, Shuji},
title = {Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography},
journal = {Children},
year = {2025},
volume = {12},
number = {9},
pages = {1131},
doi = {10.3390/children12091131}
}
EUVIMED